Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.68 |
| ▸ | CNR1 | P21554 | 5/20 | 0.68 |
| ▸ | ACHE | P22303 | 5/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376821 | 0.84 | CNR2 (0.54) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL14923511 | 0.82 | CNR2 (0.51) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL22392857 | 0.81 | CNR2 (1.00) | CNR2CNR1ACHE | |
| SCHEMBL14923443 | 0.81 | CNR2 (0.56) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL14923487 | 0.79 | CNR2 (0.53) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL3345344 | 0.78 | L3MBTL1 (0.56) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL14923442 | 0.77 | CNR2 (0.47) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL14923649 | 0.77 | MAPT (0.51) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL3380069 | 0.76 | CNR2 (0.56) | CNR2CNR1ACHEL3MBTL1MAPT | |
| SCHEMBL22151047 | 0.76 | CNR2 (0.58) | CNR2CNR1ACHEL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED | 2005-10-13 | — | — | US | disclosed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| US-6207831-B1 | A BENZOPYRAZOLE COMPOUND | NOVARTIS AG (CH) | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | CNR2 4832/4885CNR1 4588/4885ACHE 2897/4885 |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLCO1A2, ABCG2, SLCO1B1 | CNR2 4200/4885CNR1 3530/4885ACHE 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.